Jun 10, 2026 01:30AM

Sep 17, 2025 01:30AM

Mar 14, 2025 02:30AM

Mar 7, 2025 01:30AM

Dec 18, 2024 01:30AM

Sep 23, 2024 01:30AM

Sep 18, 2024 01:30AM Sensorion Reports 2024 First Half Results and Highlights Recent Updates

Sep 12, 2024 01:30AM

Jul 23, 2024 01:30AM

Jul 15, 2024 01:30AM

Jun 20, 2024 01:30AM

Mar 14, 2024 02:30AM

Mar 11, 2024 02:30AM

Feb 1, 2024 01:30AM Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation

Jan 19, 2024 01:30AM

Dec 18, 2023 01:30AM

Sep 20, 2023 01:30AM

Jul 19, 2023 01:30AM

Jul 10, 2023 01:30AM

Jul 5, 2023 01:30AM

Jun 19, 2023 01:30AM Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study

Jun 7, 2023 01:30AM

Mar 16, 2023 02:30AM

Jan 3, 2023 01:30AM

Nov 30, 2022 01:30AM

Nov 7, 2022 01:30AM

Oct 24, 2022 01:30AM

Oct 6, 2022 01:30AM Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022

Sep 22, 2022 01:30AM

Sep 14, 2022 01:30AM

Jul 1, 2022 01:30AM

Jun 7, 2022 01:30AM

Mar 17, 2022 02:30AM

Feb 3, 2022 01:30AM

Jan 17, 2022 01:30AM Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss

Oct 27, 2021 01:30AM

Sep 24, 2021 01:30AM

Sep 8, 2021 02:30AM

Jun 10, 2021 02:30AM

Apr 2, 2020 01:30AM

Mar 13, 2020 02:30AM

Feb 17, 2020 01:30AM Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study

Jan 30, 2020 01:30AM

Dec 23, 2019 11:40AM

Dec 23, 2019 01:30AM

Nov 7, 2019 01:30AM

Oct 23, 2019 01:30AM

Sep 11, 2019 01:30AM

Jul 12, 2019 01:30AM Sensorion Receives FDA IND Approval for Arazasetron (SENS-401)

Jun 28, 2019 01:30AM

322,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All